12 Best Biotech Penny Stocks to Invest In
The past few years have been a topsy-turvy ride for the biotech sector.
Cyclerion Therapeutics Inc. (CYCN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tyndall Capital Partners Jeffrey Halis | 164,777 | $530,582 | 100% | |
| 2. | Siren L.L.C. Raymond Debbane | 116,155 | $374,019 | 0.01% | |
| 3. | Renaissance Technologies Jim Simons | 10,611 | $34,167 | 0% | |
| 4. | Slate Path Capital David Greenspan | 0 | $0 | -100% | 0% |
| 5. | MFN Partners Farhad Nanji And Michael Demichele | 0 | $0 | -100% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.12 | 3,322 | Director | 24,957 | 2021-06-03 | Filing | |
| $3.12 | 92,831 | Director | 697,313 | 2021-06-03 | Filing | |
| $3.28 | 823,170 | 2,047,698 | 2021-06-03 | Filing | ||
| $3.12 | 961,538 | Large Shareholder | 7,157,601 | 2021-06-03 | Filing | |
| $2.43 | 302,000 | 1,224,528 | 2021-05-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.55 | 357,880 | Large Shareholder | 0 | 2024-11-21 | Filing | |
| $3.40 | 8 | Director | 0 | 2023-08-09 | Filing | |
| $4.00 | 1,824 | 31,599 | 2021-02-25 | Filing | ||
| $3.99 | 2,637 | 42,728 | 2021-02-25 | Filing | ||
| $3.01 | 20,107 | 251,648 | 2020-12-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 31,820 | $102,499 | 0% | |
| 2. | 23,490 | $75,638 | 0% | |
| 3. | 16,797 | $54,086 | 0% | |
| 4. | 9,667 | $31,128 | 0% | |
| 5. | 4,740 | $15,263 | 0% |
News See All
David Greenspan's Slate Path Capital is Buying Coinbase, Stitch Fix, and More
In this article, we discuss the top stocks recently acquired by David Greenspan's Slate Path Capital according to analysts.
5 Best Penny Stocks to Buy Now
Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) is an American biopharmaceutical company that offers novel drugs specializing in hematology and oncology.
5 Best Biotech Penny Stocks to Buy Now
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is a Boston-based biopharma firm founded in 2018. It is placed fifth on our list of 10 best biotech penny stocks to buy now.
Hedge Fund and Insider Trading News: Marc Lasry, Soroban Capital, Senvest Management, Alden Global Capital, Elliott Management, D1 Capital Partners, Cevian Capital, Willscot Mobile Mini Holdings Corp., Insulet Corporation (PODD), Visa Inc (V), Willscot Mobile Mini Holdings Corp (WSC), and More
Europe’s largest activist fund has built a 5% stake in the London listed insurance company Aviva as its chief executive, Amanda Blanc, became the second female FTSE 100 boss to have her strategy questioned...
Is Cyclerion Therapeutics, Inc. (CYCN) A Good Stock To Buy?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Fund and Insider Trading News: Paul Tudor Jones, Steve Cohen, Bill Ackman, Sandbar Asset Management, Corona Capital, Cyclerion Therapeutics Inc (CYCN), Chubb Ltd (CB), and More
Bill Ackman predicts 2021 will be a rewarding year for the equity market and urged investors to "go long", but the Wall Street legend and Pershing Square founder worries that irrespective of Pfizer's ...
Should You Buy Cyclerion Therapeutics, Inc. (CYCN)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Cyclerion Therapeutics, Inc. (CYCN) Is Burning These Hedge Funds
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and...
Billionaire Hedge Funds
